AR003001A1 - PHARMACEUTICAL COMPOSITION STIMULATING OSTEOGENESIS. - Google Patents

PHARMACEUTICAL COMPOSITION STIMULATING OSTEOGENESIS.

Info

Publication number
AR003001A1
AR003001A1 ARP960102893A AR10289396A AR003001A1 AR 003001 A1 AR003001 A1 AR 003001A1 AR P960102893 A ARP960102893 A AR P960102893A AR 10289396 A AR10289396 A AR 10289396A AR 003001 A1 AR003001 A1 AR 003001A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
stimulating osteogenesis
composition stimulating
osteogenesis
prophylactic
Prior art date
Application number
ARP960102893A
Other languages
Spanish (es)
Inventor
T Hoshino
H Muranishi
S Taketomi
S Iwasa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AR003001A1 publication Critical patent/AR003001A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/67—Phosphorus compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)

Abstract

La presente invención provee una composición farmacéutica que comprende una sustancia estimuladora de la osteogénesis no-péptido y un polímerobiodegradable, la cual puede ser utilizada sin riesgos como un agente profiláctico/terapéuticopara distintas enfermedades óseas (por ejemplo,fracturas de huesos)The present invention provides a pharmaceutical composition comprising a non-peptide osteogenesis stimulating substance and a biodegradable polymer, which can be safely used as a prophylactic / therapeutic agent for various bone diseases (for example, bone fractures).

ARP960102893A 1995-06-05 1996-06-04 PHARMACEUTICAL COMPOSITION STIMULATING OSTEOGENESIS. AR003001A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13803695 1995-06-05
JP1168696 1996-01-26

Publications (1)

Publication Number Publication Date
AR003001A1 true AR003001A1 (en) 1998-05-27

Family

ID=26347166

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102893A AR003001A1 (en) 1995-06-05 1996-06-04 PHARMACEUTICAL COMPOSITION STIMULATING OSTEOGENESIS.

Country Status (11)

Country Link
EP (1) EP0831808A1 (en)
KR (1) KR19990022514A (en)
AR (1) AR003001A1 (en)
AU (1) AU717260B2 (en)
CA (1) CA2221784A1 (en)
HU (1) HUP9802573A3 (en)
NO (1) NO975636L (en)
NZ (1) NZ308658A (en)
RU (1) RU2188011C2 (en)
TW (1) TW420608B (en)
WO (1) WO1996039134A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69716469T2 (en) 1996-08-26 2003-02-20 Takeda Chemical Industries, Ltd. PHARMACEUTICAL COMPOSITION CONTAINING AN OSTEOGENESE PROMOTING AGENT AND A POLYETHYLENE GLYCOL
AU4165699A (en) * 1998-06-15 2000-01-05 Takeda Chemical Industries Ltd. Composition for treating cartilage disease
CA2339662A1 (en) 1998-08-07 2000-02-17 Takeda Chemical Industries, Ltd. Benzothiepin derivatives, their production and use
EP1105140A2 (en) * 1998-08-12 2001-06-13 Takeda Chemical Industries, Ltd. Benzothiepine compounds as enhancer of cell differentiation induction factor
WO2001089521A1 (en) * 2000-05-23 2001-11-29 Takeda Chemical Industries, Ltd. Medicinal compositions containing thiophene derivatives
US6926903B2 (en) 2001-12-04 2005-08-09 Inion Ltd. Resorbable polymer composition, implant and method of making implant
JP4723864B2 (en) * 2002-12-19 2011-07-13 日本曹達株式会社 Agricultural microcapsule formulation by oil / water drying method and method for producing the same
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
EP2424488B1 (en) 2009-04-27 2023-06-07 Premier Dental Products Company Microencapsulated compositions and methods for tissue mineralization
TWI458503B (en) * 2013-04-22 2014-11-01 Medical & Pharm Ind Tech & Dev Vitamin k2 microsphere, manufacture method, use, and drug thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132651T2 (en) * 1990-05-30 2001-10-25 Takeda Chemical Industries, Ltd. Heterocyclic compounds containing sulfur
AU2808495A (en) * 1994-07-04 1996-01-25 Takeda Chemical Industries Ltd. Phosphonic acid compounds, their production and use
TW403757B (en) * 1994-12-28 2000-09-01 Takeda Chemical Industries Ltd Optically active benzothiepin derivative, its preparation and use

Also Published As

Publication number Publication date
RU2188011C2 (en) 2002-08-27
TW420608B (en) 2001-02-01
EP0831808A1 (en) 1998-04-01
NO975636D0 (en) 1997-12-04
HUP9802573A2 (en) 1999-09-28
HUP9802573A3 (en) 2000-04-28
KR19990022514A (en) 1999-03-25
WO1996039134A1 (en) 1996-12-12
NO975636L (en) 1998-01-28
CA2221784A1 (en) 1996-12-12
AU5845796A (en) 1996-12-24
AU717260B2 (en) 2000-03-23
NZ308658A (en) 1999-10-28

Similar Documents

Publication Publication Date Title
WO2002041837A3 (en) Treatment of mucositis
AR020055A1 (en) A PHARMACEUTICAL OR COSMETIC COMPOSITION CONTAINING A SUBSTANCE OF ACTIVE ENAMEL, USES OF SUCH COMPOSITION AND A METHOD TO PREPARE THE SAME.
EE04221B1 (en) Use of estrogen in the manufacture of a medicament for the treatment of physical conditions in postmenopausal individuals
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
GT199700009AA (en) COMBINED THERAPY FOR OSTEOPOROSIS
ES2140469T3 (en) COMPOSITIONS AND THERAPEUTIC AND DIAGNOSTIC METHODS FOR OBTAINING IMAGES.
ES2060310T3 (en) USE OF N-MIRISTOIL- (S) -PHENYLALANINE FOR THE OBTAINING OF MEDICINES INTENDED FOR THE TREATMENT OF DISEASES THAT INTERVENE MIRISTOILATION.
WO2001041753A3 (en) Therapeutic compositions and methods for treating periodontitis with antiinflamatory compounds
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
ES2181017T3 (en) PHARMACEUTICAL COMPOSITION CONTAINING A PROMOTING SUBSTANCE OF OSTEOGENESIS AND A POLYETHYLENE GLYCOL.
AR003001A1 (en) PHARMACEUTICAL COMPOSITION STIMULATING OSTEOGENESIS.
AR034493A1 (en) COMBINATION OF ACTIVE PRINCIPLES FOR THE MEDICAL TREATMENT OF TOXICOMANS.
ES2180729T3 (en) THERAPEUTIC COMBINED TREATMENT OF HYPERPROLIFERANT PATHOLOGIES.
DE69633396D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ACTIVIN STIMULATOR
ES2041243T3 (en) APPLICATION OF AT LEAST ONE ACTIVE INHIBITOR OR DESTRUCTIVE PRINCIPLE OF AT LEAST ONE LIVING SOLE OR VIRUS.
BR0111024A (en) Compositions and methods for breast cancer therapy and diagnosis
IT1289154B1 (en) ISOFLAVONE DERIVATIVES THEIR PREPARATION AND THEIR THERAPEUTIC USE
ES2190581T3 (en) 2-OPTICALLY ACTIVE AMINOTETRALINE, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT, ACTIVE IN THE PREVENTION AND TREATMENT OF SEPTIC SHOCK.
NZ332412A (en) use of interleuklin-10 for treating or preventing ischemia-reperfusion injury
TR199901385T2 (en) Piperidin t�revleri.
MD1270F1 (en) Method for treatment of the hand navicular bone pseudarthrosis
UA32314A (en) Method for treating necrotic pancreatitis
UA34333A (en) Method for treating severe dental fluorosis
IT1275604B1 (en) DEVICE FOR THE REDUCTION OF STENOSIS OF ORGANS OF THE HUMAN BODY